FY2017 Financial Results Conference Call

from the beginning

Financial Results for FY2017 & Outlook for FY2018

• (Cautionary Statement)(Slide only)

• Contents(Slide only)

1.Consolidated Financial Results for FY2017 Ended March 31, 2018

• Voluntary adoption of IFRS

• Financial Summary IFRS

• Financial Summary J-GAAP

• Impact from Adoption of IFRS

• Sales revenue by Business segment

• Core Operating Income by Business segment

• Petrochemicals & Plastics - Segment Analysis -

• Energy & Functional Materials - Segment Analysis -

• IT-related Chemicals - Segment Analysis -

• Health & Crop Sciences - Segment Analysis -

• Pharmaceuticals - Segment Analysis -

• Breakdown of Non-core Items

• Consolidated Balance Sheets

• Consolidated Statements of Cash Flows

2.Outlook for FY2018

• Financial Summary

• Sales revenue by Business segment

• Core Operating Income by Business segment

• Analysis of Core Operating Income

• Petrochemicals & Plastics　- Segment Analysis -

• Energy & Functional Materials - Segment Analysis -

• IT-related Chemicals - Segment Analysis -

• Health & Crop Sciences - Segment Analysis -

• Pharmaceuticals - Segment Analysis -

• Consolidated Statements of Cash Flows

(Reference: Segment Information)

• Segment Topics

• Sales revenue by Business segment I (Quarterly)

• Sales revenue by Business segment II (Quarterly)

• Operating Income /Core Operating Income by Business segment I (Quarterly)

• Core Operating Income by Business segment II (Quarterly)

• Cost Elements etc.

• Capital Expenditures by Business segment

• Estimated Capital Expenditures by Business segment

• Depreciation and Amortization by Business segment

• Estimated Depreciation and Amortization by Business segment

• Research & Development Expenses by Business segment

• Estimated Research & Development Expenses by Business segment

• Major Group Companies

• Overseas Sales revenue

• Sales revenue / Profits Transition

• Interest-bearing Liabilities / D/E Ratio Transition

• Cash Dividends / Payout Ratio Transition

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4